Flucelvax Quadrivalent Vaccine Description
Flucelvax Quadrivalent is a cell culture-based flu vaccine to help offer protection against 4 flu virus strains that are recommended by the World Health Organization the year before the current influenza season.
Seqirus's Flucelvax is the first FDA-approved flu vaccine to use cells, instead of chicken eggs, and represented the first major advance in flu vaccine manufacturing technology since flu vaccine production began in the 1930s. This modern manufacturing process allows the flu shot to be antibiotic-free, helps protect against the identified 4 flu strains for 2020-2021, and is well tolerated.
Cell-based influenza vaccine technology may offer advantages over the standard influenza manufacturing process including being more scalable and offering faster production in the event of an influenza pandemic.
Flucelvax for 2020-2021, cell- or recombinant-based vaccines are recommended to contain:
- A/Hawaii/70/2019 (H1N1)pdm09-like virus (updated)
- A/Hong Kong/45/2019 (H3N2)-like virus (updated)
- B/Washington/02/2019 (B/Victoria lineage)-like virus (updated)
- B/Phuket/3073/2013-like (Yamagata lineage) virus
In the U.S., Seqirus operates a state-of-the-art cell-based manufacturing facility in Holly Springs, NC, purpose-built in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to increase cell-based vaccine manufacturing capacity and combat pandemic influenza threats.
Flucelvax Quadrivalent Vaccine Indication
Flucelvax Quadrivalent is indicated for active immunization of people 4 years of age and older for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
Flucelvax Quadrivalent Vaccine Dosage
Flucelvax Quadrivalent is a vaccine for intramuscular injection only and is also preservative and latex-free.
Flucelvax Quadrivalent Vaccine News
September 16, 2020 - Seqirus announced the publication of real-world evidence on the company's cell-based quadrivalent influenza vaccine (QIVc) in the peer-reviewed medical journal Vaccine. Study results indicate QIVc was more effective compared with standard, egg-based quadrivalent vaccine (QIVe-SD) in preventing influenza-related hospitalizations/ER visits, all-cause hospitalizations, and hospitalizations/ER visits related to serious respiratory events.
Flucelvax Quadrivalent Vaccine Clinical Trials
Clinical Trial NCT03165617: Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age
Clinical Trial NCT04074928: Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
Clinical Trial NCT03438487: Flucelvax (TIVc or QIVc) Pregnancy Registry
Clinical Trial NCT03932682: Efficacy Study With QIVc in Pediatric Subjects